Athersys (ATHX) Stock Declines 19% Amid Biotech Rout
Tweet
Share
E-mailGet Alerts ATHX Hot Sheet
Join SI Premium – FREE
Athersys, Inc. (Nasdaq: ATHX) declined 19% on Monday. Athersys is a clinical-stage biotechnology company that develops stem cell products for treating immune disorders. Neuralstem, Inc. (NYSE: CUR) and StemCells Inc. (Nasdaq: STEM) also declined.
Broadly, biotech stocks sold off on Monday, with iShares Nasdaq Biotechnology ETF (Nasdaq: IBB) lower by 3.5%. ProShares Ultra Nasdaq Biotechnology (Nasdaq: BIB) saw heavy volume.
Broadly, biotech stocks sold off on Monday, with iShares Nasdaq Biotechnology ETF (Nasdaq: IBB) lower by 3.5%. ProShares Ultra Nasdaq Biotechnology (Nasdaq: BIB) saw heavy volume.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Molina Healthcare to join S&P MidCap 400, Construction Partners to join S&P SmallCap 600
- Adobe has received a takeover approach by a Big Tech company - Betaville
- Trump: Will Call Carney About Wildfires
Create E-mail Alert Related Categories
ETFs, Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
